Angiochem Inc.

Conjuchem, Inc.

Raptor Pharmaceuticals Inc.

Conjuchem Biotechnologies Inc.

Raptor Pharmaceutical Corp

Bio-k Plus International, Inc.

Transfert Plus, S.e.c.

Transfert Plus

Richard Beliveau

Michel Demeule

Christian Che

Anthony Regina

Karen Thibaudeau

Reinhard Gabathuler

Alain Larocque

Xicai Huang

Cyndia Charfi

Jean-Christophe Currie

Borhane Annabi

Joseph Yang

Malcolm L Kennard

Michele Rasamoelisolo

Dominique P Bridon

Dominique Bridon

Jean-Paul Castaigne

Catherine Gagnon

Jonathan Michaud-Levesque

Francois-Marie Luquet

Yanick Bertrand

Yannève Rolland

Julie Jodoin

Denis Gingras

Carine Nyalendo

Stephane Barakat

Reinhardt Gabathuler

The present invention relates to carriers, conjugate and pharmaceutical compositions and their use to increase the potency of drugs and to modify the pharmacokinetics of compounds. More particularly, the present invention relates to conjugates comprising the carrier described herein and their use in the treatment and diagnostic of cancer.

Potentiation of anticancer agents

Based on the discovery that a soluble polypeptide including a nonphosphorylatable form of the MT1-MMP cytoplasmic domain is capable of inhibiting MT1-MMP in a dominant negative manner, the present invention provides compositions including MT1-MMP inhibitors such as peptide inhibitors, and methods for treating diseases associated with MT1-MMP activity. Such diseases include cancer, arthritis, and heart disease, and vascular disease.

Membrane type-1 matrix metalloprotein inhibitors and uses thereof

The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates. The present invention also relates to the use of these polypeptides for transporting a compound or drug across the blood-brain barrier of a mammal and in the treatment and diagnosis of neurological diseases.

Aprotinin polypeptides for transporting a compound across the blood-brain barrier

The present invention is directed to polypeptides (e.g., fragments) derived from P-glycoprotein and caveolin-1 which are capable of inhibiting the interaction between these two proteins. Inhibition of this interaction leads to increase of efflux of compounds that are transported by P-gp. The invention further includes methods of treating patients having diseases that benefit from increased P-gp-mediated efflux. Such diseases include neoplasms such as cancer and neurological diseases such as neurodegenerative diseases.

Compounds for stimulating P-glycoprotein function and uses thereof

This invention provides conjugates of therapeutic or active agents with melanotransferrin or with other ligands of a melanotransferrin receptor, melanotransferrin receptor modulators, and related compositions and methods for modulating blood-brain barrier transport by providing methods of screening and selecting such conjugates, ligands, and modulators in vitro and in vivo, and methods of use of such conjugates, modulators and ligands in diagnosis and the treatment of diseases, including particularly diseases of the central nervous system or lysosomal storage diseases.

Compositions and methods for modulating blood-brain barrier transport

A lactic composition containing at least a bacterial strain selected from the group consisting ofand a mixture ofand, and a whole broth of the bacterial strain or the mixture of the bacterial strains, is useful for the prevention or treatment of disorders which are angiogenesis dependant. Both the lactic composition and its supernatant can be used for prevention or treatment of angiogenesis dependant disorders. The supernatant of the lactic composition exhibits antiangiogenic properties.

Use of strains of lactobacillus and by-products thereof for inhibiting formation of blood vessels

Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.

Long lasting anti-angiogenic peptides

Compositions for modulating blood-brain barrier transport

The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptide derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides. The present invention also relates to the use of these polypeptide for transporting a compound or drug across the blood-brain barrier of an individual and in the treatment and diagnosis of neurological diseases.

Molecules for transporting a compound across the blood-brain barrier

Growing community of inventors

Verdun, Canada

Richard Beliveau